Table of Contents
Executive Summary
5
Hungary Pharmaceuticals And Healthcare Industry SWOT 6
Hungary Political SWOT 7
Hungary Economic SWOT 8
Hungary Business Environment SWOT 9
Pharmaceuticals & Healthcare Business Environment 10
Table: Central And Eastern Europe Pharmaceuticals Business Environment Ratings For Q209 10
Limits to Potential Returns 11
Hungary - Market Summary12
Regulatory Regime13
Recent EU Regulatory Developments 14
Intellectual Property Regime 15
Pricing Regime 16
Table: Hungary - Pharmaceutical Price Build-Up 17
Table: Hungary - Average Pharmacy Mark-Up 18
Reimbursement Regime 18
Price Cuts19
Pricing and Reimbursement Reforms 20
Industry Developments22
Epidemiology 22
Table: Disease Burden In CEE 22
Healthcare Financing 23
Healthcare Reforms 24
Hospital Sector Reforms 25
Research and Development 27
Table: Special Incentive Package For Investors Willing To Establish An R&D Facility Worth At Least EUR10mn in Hungary 28
Biotechnology Sector 28
Medical Devices 29
Industry Forecast Scenario 31
Overall Market Forecast 31
Table: Hungary' s Drug Market Forecast, 2004-2013 32
Key Growth Factors - Industry 33
Table: Hungary' s Health Expenditure Indicators, 2004-2013 33
Key Growth Factors - Macroeconomic 34
Table: Hungary- Economic Activity 36
Prescription Market Forecast 37
Table: Hungary' s Prescription Market Indicators, 2004-2013 (HUFmn unless otherwise) stated) 38
OTC Market Forecast 39
Table: Hungary' s OTC Market Indicators, 2004-2013 (HUFmn unless otherwise) stated) 40
Patented Market Forecast 41
Table: Hungary' s Patented Drug Market Indicators, 2004-2013 42
Generics Market Forecast 43
Table: Hungary' s Generics Market Indicator Forecasts, 2004-2013 44
Export/Import Forecasts 45
Table: Hungary' s Import/Export Market Forecasts, 2004-2013 (US$mn) 46
Medical Devices Forecast 47
Table: Hungary' s Medical Device Market 2004-2013 48
Other Healthcare Data Forecasts 49
Table: Hungary' s Other Healthcare Data, 2004-2013 49
Key Risks To BMI' s Forecast Scenario 49
Competitive Landscape50
Table: Leading Pharmaceutical Companies By Ownership 51
Domestic Price Cuts Calculated For Total Egis Portfolio 53
Wholesale and Retail Pharmacy Sector 55
Company Monitor57
Multinational Companies 57
Pfizer 57
Novartis 59
Sanofi-Aventis 60
GlaxoSmithKline 62
Merck & Co 63
Eli Lilly 64
Krka 66
Domestic Manufacturers 68
Gedeon Richter 68
Egis Pharmaceuticals (Servier) 72
Country Snapshot: Hungary Demographic Data 75
Section 1: Population 75
Table: Demographic Indicators, 2005-2030 75
Table: Rural/Urban Breakdown, 2005-2030 76
Section 2: Education And Healthcare 76
Table: Education, 2002-2005 76
Table: Vital Statistics, 2005-2030 76
Section 3: Labour Market And Spending Power 77
Table: Employment Indicators, 2001-2006 77
Table: Consumer Expenditure, 2000-2012 (US$) 78
Table: Average Annual Wages, 2000-2012 78
BMI Forecast Modelling79
How We Generate Our Pharmaceutical Industry Forecasts 79
Pharmaceutical Business Environment Ratings Methodology80
Ratings Overview 80
Table: Pharmaceutical Business Environment Indicators 81
Weighting 82
Table: Weighting Of Components 82
Sources 82
| 
View Cart
